Introduction
Acute myelogenous leukaemia (AML) is a clonal haematopoietic stem cell disorder. 1 Immune activity has been implicated in the clonal evolution of childhood leukaemia, 2 yet host immune inactivity, or immunoparesis, [3] [4] [5] [6] as well as tumour evasion of immune recognition 7, 8 have been emphasised in studies of AML pathogenesis. Experimental studies of the mechanisms of immune tolerance to AML have led to novel therapies designed to modulate the immune response, including antibody, 9 cytokine 10 and dendritic cell-based treatments. 11 In AML, little is known about the potential of patients to respond to these immunotherapies, yet their effective implementation would require intact responder cell populations. Vaccination strategies studied in normal individuals may not even apply to patients with AML in remission because of the chemotherapy regimens used to treat the disease. 4 Application of a method that could simultaneously evaluate immune activity and potential in patients with leukaemia would be useful. 12 The aim of this study was to develop a simple method wherein the absolute number of immune effector cells in the peripheral blood of AML patients and the cytokines these cells were producing natively, without added in vitro stimulation, could be evaluated within a small volume of whole blood. The use of whole blood rather than separated mononuclear cells (MNCs) allowed for minimal loss of cell subsets in processing, simplicity of the procedure and direct measurement of ongoing cytokine production in the presence of autologous plasma. In total, 13 patients with AML pre-and postchemotherapy and eight healthy individuals were evaluated for the absolute numbers of circulating T cell, NK cell and myeloid cell subsets and their respective unstimulated profiles for the ongoing secretion of interleukin (IL)-4, IL-10, IL-12 and (interferon) IFN-g. The results show that the lymphocytes in patients with AML were present in normal numbers and were more active in the secretion of cytokines than was previously thought. Interestingly, leukaemic blasts produced predominantly IFN-g, suggesting a type 1 cytokine profile at disease presentation. There was a trend towards lower lymphocyte counts post chemotherapy though this was significant only in the NK cell subset after the second chemotherapy. A prominent CD8 lo / CD3
lo-int T-cell population emerged in four out of nine postchemotherapy samples after recovery from nadir. Cytokine expression of postchemotherapy samples resembled normal cell profiles with less active secretion of cytokines by T-cells than was seen in the same patients at presentation. This form of assessment may be helpful in elucidating mechanisms of leukaemogenesis and in assisting therapeutic intervention in AML.
Methods

Samples
In all, 13 consecutive adult patients with AML presenting to Northwick Park Hospital between May 2000 and September 2001 and eight healthy adult volunteers (age range 25-67 years old) were studied. The characteristics of the AML patients studied and the type of chemotherapy they received are shown in Table 1 . AML samples were collected at the time of initial presentation or relapse. Overt infection was present in only one of the patients at the time of sample collection (sample 07, Table 1 ). Postchemotherapy samples were also studied in nine of the AML patients only after the first and/or second chemotherapy courses. Samples were collected just prior to the start of the next course of chemotherapy when the patients were most well. For all samples, at least 2 ml of peripheral blood (PB) was collected in vacutainert tubes containing heparin (Becton Dickinson, Plymouth, UK) after informed consent and processed within 1 h of collection.
Immunotech, Marseilles, France) and anti-CD3 PC5-conjugated (clone UCHT1, Immunotech) antibodies were used as a cocktail. In three AML samples, anti-CD33 (clone WM-54, Dako, Cambridgeshire, UK) or anti-CD34 FITC-(clone 8G12, Becton Dickinson) conjugated antibodies were used instead of anti-CD45 antibody to identify the AML blasts. Isotype controls for IgG1 FITC (Becton Dickinson), ECD (Immunotech) and PC5 (Immunotech) were used to set positive and negative regions for gating during analysis. For intracellular staining, PE-conjugated anti-IL-4 (clone 3007.11, R&D, MN, USA), anti-IL-10 (clone JES3-9D7, Serotec, Oxford, UK), anti-IL-12 p40/p70 (clone C11.5, BioSource, CA, USA) and anti-IFN-g (clone D9D10, Serotec) antibodies were used. Anti-CD8 PE-(clone SK1, Becton Dickinson), FITC-(clone SK1, Becton Dickinson), ECD-and PC5-(clone B9.11, Immunotech) conjugated antibodies were used for off-line compensation.
Whole blood assay
The method was adapted from one previously described. 13 Under sterile conditions, 50 ml of whole blood, 50 ml of X-VIVO 15 medium and 50 ml of additive solutions in X-VIVO 15 medium were added per antibody-staining condition, for a total of 150 ml per FACS tube (Greiner Labortechnik, Germany). For each antibody-staining parameter, two conditions were tested: (1) medium-only control and (2) monensin (Calbiochem, CA, USA) 3 mM only. Addition of monensin results in the accumulation of cytokines in the Golgi apparatus of the cell because of the inhibition of intracellular transport processes. Samples were evaluated for their native cytokine production only and without added in vitro stimulation. Cell suspensions were left undisturbed for 6 h at 371C in a humidified incubator with 5% CO 2 . Antibodies to surface markers were then added (5 ml of each) and the cells were incubated at room temperature in the dark for 15 min. Red cells were lysed with 250 ml of Optilyse C (Immunotech, Marseilles, France), the samples were mixed well with a vortex and incubated at room temperature for 15 min in the dark. The cells were washed with PFAE buffer (PBS with 2% FCS or BSA, 0.02% sodium azide, and 1 mM EDTA), and 100 ml of fixative (Leukoperm Reagent A, Serotec) was added. After incubation at room temperature for 15 min in the dark, the cells were again washed and 100 ml of permeabilisation reagent (Leukoperm Reagent B, Serotec) was added. A total of 2 ml of FCS was added to each sample for nonspecific blockade of Fc receptors followed by 5 ml of anti-cytokine antibodies. The cells were incubated for 30 min at room temperature in the dark, washed with PFAE and resuspended in 1% paraformaldehyde for acquisition within 48 h.
Flow cytometry acquisition
The cells were acquired on an EPICS XL flow cytometer (Beckman Coulter, High Wycombe, UK) equipped with a 488 nm cooled Argon laser set-up for four excitation-parameter evaluation. At the time of acquisition, 50 ml of Flow-Countt fluorospheres (Beckman Coulter) at a fixed concentration was added to each tube. Samples were acquired for 300 s or for the time needed to acquire 15 000 cells in the blast region of the side scatter (SSC) vs forward scatter (FSC) plot.
Analysis of flow cytometry data
Flow cytometry acquisition data were analysed with WinList 5.0 (Verity Software House, ME, USA) software. Compensation was done off-line utilising the WinList software program and minimised user-dependent variability. Off-line compensation also accommodated re-validation of the analysis results and more rigorous examination. Regions were set on the myeloid and lymphoid cells based on the CD45 vs SSC plot (Figure 1a (iii) and b(iii) for normal and AML blood respectively).
14 Lymphoid subsets were further defined based on the CD3 vs CD8 2-parameter histogram [ Figure 1a (iv) and b(iv) for normal and AML All patients were in remission with the first course of chemotherapy except AML 11.
c Postchemotherapy samples were evaluated on these patients, either after each of the first two courses (AML 02-04, 07, 08, 10), or after only the first course (AML 13), or after only the second course (AML 05 and AML 09). /l and plts >100 Â 10 9 /l; FLAG-Ida = FLAG, idarubicin 12 mg/m 2 D1-3; = patient death.
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Figure 1
Cell subset analysis in normal (a) and leukaemic (b) blood plots as defined by SSC vs FSC (i), CD45 vs FSC (ii), CD45 vs SSC (iii) and CD3 vs CD8 (iv). Lymphocyte subsets, monocyte and blast regions were defined by the CD45 vs SSC plot (iii) and then backgated into the remaining plots. The lymphocyte subset was further subdivided based on the CD3 vs CD8 plot (iv) into CD8 + and CD8 À T-cells and CD8 þ NK cells. The absolute number of cells in the peripheral blood was evaluated by comparing the number of events in the region of interest to those in the fluorescent bead region (ii) and multiplying by the bead concentration (units/ml). Figure 1a (ii) and b(ii) for normal and AML, respectively]. Based on the number of events in the cell region of interest and the number of events in the bead region and a known bead concentration used at a 1:1 ratio during acquisition, the absolute number of cells in the region per microlitre whole blood was determined. Comparing one-parameter histogram plots for each cell subset, the samples with nothing added to them (control samples) were subtracted from those samples that had been exposed to monensin (test samples) for 6 h (Figure 2 ). The result was representative of the native cytokine production, without added in vitro stimulation, during the 6 h assay. Super-enhanced D max normalised subtraction (SED) statistics were performed using the WinList software program. If the subtraction resulted in a negative value (ie, reversal of the test and control histograms to be subtracted), a value of '0' was recorded. Based on the per cent positive after the subtraction and the number of total cells in the regions subtracted, an absolute number of cells expressing cytokine in the region studied was determined per microlitre. In preliminary studies, positive cytokine staining could be blocked using excess anti-cytokine antibody not conjugated to fluorochrome, thereby indicating the specificity of the technique for the detection of intracellular cytokine expression.
Statistical analysis
Flow cytometry histogram subtraction statistics: SED statistics were used for the channel-by-channel analysis of flow cytometry data using the WinList 5.0 software package. 15 The D max and Kolmogorov-Smirnov (K-S) statistics were used to assess the significance of a positive result by calculating the critical D value (D crit ) with the following equation:
where D max is the maximum value between the test and control samples after the two histograms have been converted into cumulative normalised histograms, n 1 is the number of events in the test sample and n 2 is the number of events in the control sample 16 (North M, Farrant J, Lane A, Knight S, submitted). Only positive values that gave a D crit with a Po0.05 were accepted. If the D crit (K-S critical value) resulted in a P40.05, then the percentage of cells producing cytokine in the sample was considered to be '0'.
Graphing statistics: The SigmaPlot 4.0 (SPSS software products, IL, USA) statistical software package was used to calculate the difference between and within groups of data obtained by SED and K-S statistics described above. Paired and unpaired t-tests were used to evaluate the AML pre-and postchemotherapy sample differences and unpaired t-test was used to assess differences between the normal and leukaemic samples. Super-enhanced D max normalised subtraction. One-parameter histograms for the intracellular staining of IL-12 in CD8 + T-cells in a blood sample with and without added monensin is shown as an example of the subtraction technique. Intracellular cytokine production in each cell subset was determined by subtracting the sample without monensin from that with monensin with the SED program provided in the Winlist 5.0 software package. The percentage of cells positive was then converted to an absolute number of cells producing the cytokine/ml by multiplying with the number of cells/ml in the regions subtracted. A P-value was then determined using the D value and the number of events in the gates being subtracted.
Results
Absolute number of cells in circulation
The absolute number of lymphocytes in the blood of patients with AML was not significantly different from that of healthy individuals (Figure 3a -c). Two groups of patient samples could be identified based on cell subset numbers: one with high lymphocyte numbers and one with low cell numbers (Figure 3b ). The separation of samples based on lymphocyte number was independent of the AML subtype. Seven of the AML patients had high CD8
+ T-cells in the circulation and also had higher numbers of CD8 À T-cells and AML blasts; higher NK cells were seen in six of these seven samples. Six of the patients with low CD8 + T-cell number also had lower numbers of CD8 À T-cells, NK cells and AML blasts. This increase in cellularity seemed to be a true distinction between the samples and not an artefact of the method, since the increase in the number of lymphocytes was not proportional to the increased number of AML blasts. Overall, in both high and low count subsets, there was a trend for lower CD8
À T-cell counts and CD8 + NK cells but higher numbers of CD8 + T-cells in AML patients compared with normals ( Figure 3a -c), which was mirrored in the lower CD4 + :CD8 + ratios ( Figure 3f ). The lymphocyte numbers after recovery from each chemotherapy remained lower than the presentation counts and than those in normals, with the only significant decrease in the CD8 + NK subset after recovery from the second chemotherapy ( Figure 3c ; P ¼ 0.01 in comparison with normal). Monocyte counts were significantly elevated after recovery from each chemotherapy course compared with normal steady-state numbers (Figure 3d ; Pr0.01), as expected in the recovery phase. Of the 15 postchemotherapy samples evaluated (seven after recovery from the first course and eight after recovery from the second course), a distinct CD8 lo /CD3 lo-int population was noted ( Figure 4c ) in four of the samples (samples 02, 04, 07 and 10 from Table 1 ). The appearance of this population was independent of the age of the patient, AML subtype, type of chemotherapy received or number of chemotherapy courses completed. In one patient sample (sample 07), it accounted for the majority (over 5000 cells/ml) of total cells in the circulation at the point of sample procurement (Figure 3b , P2). The expression of CD45 on these CD8 lo /CD3 lo-in T-cells was low in intensity ( Figure 4b ), suggesting that they constituted a more immature population of lymphocytes recovering after chemotherapy.
Production of cytokines
Lymphoid cell subsets: Intracellular cytokine production by whole-blood leukocytes in their native state was evaluated by flow cytometry in the absence of in vitro stimulation. The number and percentage of cells producing the cytokines IL-4, IL-10, IL-12 and IFN-g in each cell subset are shown in Figures 5 and 6. The major finding from this study was that some of the CD8 + and CD8 À T-cells and NK cells from the blood of a proportion of both the normal control individuals and the AML patients produced each cytokine tested without added in vitro stimulation. Cancer patients are generally believed to be immunosuppressed. However, there was no evidence of a significant change in the cytokine production in the cell subsets of patients with AML; there was even a trend for higher absolute numbers ( Figure 5 ) and proportions ( Figure 6 ) of CD8 + and CD8
À lymphocytes making IL-10, IL-12 and IFN-g compared with normals and with the same patients postchemotherapy (P1). This suggested a more activated phenotype for the lymphocytes in AML patients at presentation. There was no correlation between a high CD8 + and CD8 À T-cell count and cytokine production in the AML patients. The chemotherapy did not significantly alter the cytokine profiles; instead of reduced cytokine activity there was again a trend towards increased IL-10, IL-12 and IFN-g producing lymphocytes after the second chemotherapy (P2) compared with those after the first chemotherapy (P1) and those of the normal controls ( Figures 5  and 6 ).
The intensity of intracellular cytokine staining, as measured by the postive:control intensity ratio (IR; Figure 2 ), was low for all cytokine-producing cells. The intensity of expression of IL-10 was slightly higher than that of IL-12 and IFN-g in the cohort of AML patients [for CD8
À T-cells, IL-10 median IR 1. Myeloid cell subsets: The percentage of monocytes producing IL-10 after recovery from the second chemotherapy (P2) was the same as that of normals ( Figure 6 ), but the absolute number was increased ( Figure 5 ). This apparent discrepancy between the percentage and absolute number of IL-10 producing monocytes reflected the increased monocyte numbers after recovery (Figure 3d ). The intensity of expression of all cytokines measured in the monocyte population was low and similar in all cohorts studied.
Interestingly, nine of the 13 AML samples displayed IFN-g or IL-10 expression in the leukaemic blasts. Six of these samples produced IFN-g and IL-10 concomitantly. When compared with the small numbers of normal circulating precursor cells (CPCs) that occupied the same location on a CD45 vs SSC plot (Figure 1,  iii) , only the percentage of blasts that produced IFN-g was significantly increased (P ¼ 0.03). Similar to the findings in the lymphoid subsets, the IR for IL-10 expression was slightly higher than for IL-12 and IFN-g in the AML blasts [median IL-10 IR 1.88 (range 1.14-2.94), median IL-12 IR 1.56 (range 1.18-2.00), median IFN-g IR 1.46 (range 1.13-1.77)]. Cytokine production and the type of cytokine expressed by all cell types evaluated pre-and postchemotherapy was not correlated with prolonged remission status.
Discussion
We have described a simple whole-blood assay that provides simultaneous information about the absolute numbers of different cell subsets in the peripheral blood and the cytokines that these cells produce. This technique was applied to the immune monitoring of patients with AML. The absolute number of circulating lymphocytes in AML patients at presentation was not significantly different from that in normal healthy controls. Cells producing the cytokines IL-4, IL-10, IL-12 and IFN-g were detected in the blood of normal individuals and were also present in blood from AML patients suggesting that the immune system in these patients is more activated than was previously thought. 3 Studies evaluating lymphocytes in leukaemia have focused on the per cent of cells present in whole blood or separated MNC preparations. [17] [18] [19] These methods based on proportions may misrepresent absolute numbers of cells circulating in the PB and, when combined with intracellular cytokine production, can lead to incorrect conclusions regarding the immune status of + :CD8 + ratio (f) were seen between the groups studied. NK cells were significantly lower than normal after recovery from the second chemotherapy only (c). Monocytes were increased after each chemotherapy (d). Horizontal bars within each graph denote the median of the sample distribution (normal n ¼ 8, AML n ¼ 13, P1 n ¼ 7, P2 n ¼ 8). CPC ¼ circulating precursor cells; P1 ¼ postchemotherapy #1; P2 ¼ postchemotherapy #2.
Cell number and cytokine secretion in AML N Panoskaltsis et al individuals with disease. 20 The method described in this work provides the advantage of single-cell analysis of cytokine production by four-colour flow cytometry utilising a minimal amount of whole blood per test. Both lymphoid and myeloid compartments and their respective intracellular cytokine patterns can be evaluated simultaneously and the use of standardised fluorescent counting beads provides enumeration of cytokine-producing populations. The technique is simple and can be performed in any well-equipped haematology laboratory. Minimal manipulation inherent in the whole-blood method reduces selective cell loss and cell activation by processing and allows for the cell populations to be studied in a native state and in a more 'natural' environment with host serum and plasma factors present. Comparison of samples with and without the addition of monensin for their native cytokine profile avoids the pitfalls of using isotype controls in the evaluation of intracellular cytokine production and the poorly measured contribution of cytokine already stored within cellular compartments at the time of evaluation (North M, Farrant J, Lane A, Knight S, submitted). It provides a clear image of cytokine production during the 6 h assay. Furthermore, the WinList software program and SED method of flow cytometry analysis provide objective compensation of files off-line and robust evaluation of small but significant shifts in cytokine production that are relevant in cell-cell interactions. The potential for automatic data transfer from WinList into Excel spreadsheets makes this method practical for application in the clinical setting (North M, Farrant J, Lane A, Knight S, submitted).
Cytokine milieux may be instrumental in polarising the immune response toward type 1 or type 2 activity. 21 Th1 and Th2 CD4 + T-cell responses are characterised by the secretion of cytokines IFN-g/IL-2 and IL-4/IL-10, respectively. 22 Likewise, Tc1 and Tc2 describe the cytokine skew for CD8 + T-cell subtypes. 23 The cytokines and signals that initiate the immune response originate with the dendritic cell, and a cascade of autocrine and paracrine loops then propagate this response, with termination likely effected by apoptosis. 21 Attempts have been made to elucidate these type 1 and type 2 responses in patients with leukaemia. Whereas immune activity with respect to cytokine profiles has been evaluated in patients with chronic lymphocytic leukaemia (CLL), [24] [25] [26] acute lymphocytic leukaemia (ALL), 19, 27 and chronic myelogenous leukaemia Percentage of cells in each subset producing intracellular cytokine IL-4, IL-10, IL-12 and IFN-g in normal controls and in AML patients before and after chemotherapy. There were significantly more leukaemic blasts making IFN-g compared with the normal precursor population. There was a tendency for more cytokine-producing CD8 À and CD8 + T-cells in the blood of patients with AML at presentation compared with the normal and postchemotherapy samples. Horizontal bars within each graph denote the median of the sample distribution (normal n ¼ 8, AML n ¼ 13, P1 n ¼ 7, P2 n ¼ 8). CPC ¼ circulating precursor Cell, P1 ¼ postchemotherapy #1, P2 ¼ postchemotherapy #2.
Cell number and cytokine secretion in AML N Panoskaltsis et al (CML), 17, 18, 28 studies in AML have been lacking. The extent and type of cytokine activity shown in the present work in patients with untreated AML were unexpected (Figures 5 and 6 ). The tendency for IFN-g, IL-12 and IL-10 with little IL-4 secretion by lymphocyte subsets would suggest more of a type 1 skew in the cytokine balance in AML. The presence of both IL-12 and IL-10 may reflect the reciprocal regulation that these two cytokines have on each other. 29 An interesting finding in this study was the prominent IFN-g secretion by the AML blasts. This type 1 cytokine pattern in the cells of patients with AML is undergoing further analysis (Panoskaltsis N, Knight SC, Reid CDL, manuscript in preparation) and may imply an infectious or inflammatory component to AML as has been suggested for childhood ALL 2 and the preleukaemic states. 30 IL-12 is not usually considered as part of the secretion pattern of type 1 T-cells, 22, 23, 29 although a recent human study in multiple sclerosis detected IL-12 production by flow cytometry in stimulated CD4 + and CD8 + T-cells. 31 In our study, the fact that the antibody used was specific for the p40/p70 functional unit and that IL-12 secretion could be further stimulated with the addition of Phorbol, 12-Myristate, 13-Acetate (PMA) and calcium ionophore (Panoskaltsis N, Knight SC, Reid CDL, manuscript in preparation) suggested that this cytokine should be examined more thoroughly for its role in T-cell cytokine networks. Low level secretion of cytokines and high receptor uptake can mask cytokine expression important in cell-cell interactions (Maroof A, Penny M, Kingston R, Murray C, Islam S, Knight SC, submitted).
Normal to high T-cell numbers have been noted in patients with CML 17 and B-cell-CLL 32,33 and were composed predominantly of CD8 + T-cells resulting in a reduced CD4 + :CD8 + ratio, similar to that found in our study. Postchemotherapy lymphocyte numbers are dependent on the type of chemotherapy 4 and may account for the absence of a significant difference in the number of T-cells pre-and postchemotherapy in our study. Application of this method to a larger cohort of patients is planned to evaluate further the significance of the normal absolute number of lymphocytes in AML patients pre-and postchemotherapy. There was a significant decrease in the CD8 + NK cell subset of lymphocytes after the second chemotherapy (Figure 3c ). Low CD8 + NK cell numbers with cytotoxic capability after therapy have been previously described and correlated with poor disease prognosis. 34 In our present work, postchemotherapy CD8 + NK cell numbers could be correlated to remission status in six of the 13 AML patients. Three of these six patients relapsed within 1 year and had NK cell counts of 25.4, 14.1 and 10.1 cells/ml in P1 (the latter one) or P2. The remaining three patients were in remission (41 year; Table 1 ) at the time of this report and had NK cell counts of 55.8, 65.5 and 3.8 cells/ml in P2. Hence, lower postchemotherapy CD8 + NK cell counts in patients with early relapse was indicated. However, a larger cohort of AML patients undergoing chemotherapy would be required to evaluate the statistical significance of this observation.
A significant increase in absolute numbers of monocytes was noted after recovery from chemotherapy (Figure 3d ). High monocyte numbers are expected to occur following recovery from nadir, since these cells are among the first to undergo mobilisation. Increased IL-10 secretion in the postchemotherapy monocytes may be a reflection of the granulocyte-colony stimulating factor (G-CSF) all AML patients received during nadir, [35] [36] [37] even though all patients had been off G-CSF therapy for at least 7 days at the time of sample collection. Conversely, the reconstitution of a normal haematopoietic compartment may inherently be of a type 2 'default', and cellular reconstitution in the absence of disease may revert back to this cytokine secretion pattern (Panoskaltsis N, Knight SC, Reid CDL, manuscript in preparation).
Of particular interest was the emergence of a prominent CD8 lo /CD3 lo-int T-cell population after recovery from nadir in four of the nine patients examined postchemotherapy. The appearance of this population has not previously been described and was independent of the type of chemotherapy used for treatment. It may have been more dependent on timing of the blood sample since the postchemotherapy blood was always taken near or on the day of the next course of chemotherapy when the patients were clear of infection and on no drug therapy. If this population were one of 'lymphocyte rebound' postnadir, then timing of collection would be crucial since interindividual differences in its emergence would exist. Owing to the method applied in this study to identify lymphocyte subsets, it is unclear if this subset is also CD4 + . Dim CD45 staining (Figure 4 ) implies a less mature subset of recovery Tcells. Above normal CD8 + T-cell numbers have been noted in the initial phases of postchemotherapy cell recovery 4, 38 and are mostly of the mature, activated CD28 À subtype. 38 Further clarification of the identity of this population of CD8 lo T-cells is being pursued. It may have particular relevance to the study of immune reconstitution after chemotherapy and stem cell transplantation, not only for the therapy of infectious complications of these treatments, but also for optimal timing of vaccination against infectious pathogens and tumour antigens. With immunotherapy in mind, future questions should focus on whether this CD8 lo T-cell population is a naive cell subset, able to be primed by dendritic cells to enhance the response towards a specific antigen, or one that is already committed and therefore not amenable to further manipulation. If it is an activated cell population, identification of its antigenic target may be instructive in the understanding of postmyelo-reductive and -ablative immune reconstitution and antigenic determinants important in this selective T-cell recovery.
A simple whole-blood method has been described for the evaluation of the immune activity in patients with AML. Contrary to older data, 3 lymphocyte numbers at presentation were similar to those in normal, and cytokine production patterns suggested a skew towards a type 1 response. This approach to the study of cell subsets and intracellular cytokines in patients undergoing treatment could be used to assess immune status at diagnosis, its reconstitution during treatment and to monitor and guide immunotherapy in AML.
Synopsis: Method in focus Assay characteristics
A whole blood assay is described for the identification of myeloid and lymphoid cell subsets and their intracellular cytokine production using flow cytometry. The method combines a whole blood assay for the evaluation of intracellular cytokine production in lymphoid subsets 39 with the principles of clinical flow cytometry for the evaluation of leukaemic blast populations by the use of the CD45 vs side scatter profile. NK cells, monocytes, granulocytes, and circulating precursor cells or leukaemic blasts. The fourth channel is used for evaluation of intracellular cytokines. In contrast with other intracellular cytokine assays, the cells are not stimulated in vitro and ongoing cytokine production is identified. This ongoing cytokine activity is assessed by the use of the WinList programme (Verity Software House, ME, USA) 41 for flow cytometry data analysis that enables sensitive measurements of low-level cytokine production verified using KolmogorovSmirnov (K-S) statistics. 42 The unique technique uses fourcolour flow cytometry and objective compensation off-line, fluorescent counting beads to assess the absolute number of cells, super-enhanced normalised subtraction to evaluate the level of positivity, and has the option of automation with direct data transfer to Excel for analysis.
Protocol
The operator should be familiar with the principles and practice of flow cytometry as well as have rudimentary knowledge of the analysis of the data generated.
(1) Samples. Immediate anticoagulation of the peripheral blood sample is required. In our hands, vacutainert tubes containing heparin (Becton Dickinson, Plymouth, UK) are practical and provide sufficient anticoagulation. Also, quick processing of whole blood samples is optimal. We have found that whole blood cell populations change their scatter characteristics and there is an artefactual change in cell subset number because of surface adhesion after only 6 hs. The method is adapted from one previously described. 39 Under sterile conditions, 50 ml of whole blood, 50 ml of X-VIVO 15 medium and 50 ml of additive solutions in X-VIVO 15 medium are added per antibody staining condition, for a total of 150 ml per FACS tube (Greiner Labortechnik, Germany). For each antibody staining parameter, two conditions are tested: (1) medium-only control and (2) monensin (Calbiochem, CA, USA) 3 mM only. Addition of monensin results in the accumulation of cytokines in the Golgi apparatus of the cell owing to the inhibition of intracellular transport processes. Samples are evaluated for their ongoing cytokine production only and without added in vitro stimulation. Cell suspensions are left undisturbed for 6 h at 371C in a humidified incubator with 5% CO 2 . Antibodies to surface markers are then added (5 ml of each, although this amount should be optimised for each system) and the cells are incubated at room temperature in the dark for 15 min. For the compensation panel, five tubes are set aside and treated in the same way as the medium only control: one tube has no antibodies added to establish the amount of autofluorescence and each of the remaining four tubes has one of the CD8-conjugated antibodies added. Red cells are lysed with 250 ml of Optilyse C (Immunotech, Marseilles, France), the samples are mixed well with a vortex (this is important for optimal lysis) and incubated at room temperature for 15 min in the dark. The cells are washed with PFAE buffer (PBS with 2% FCS or BSA, 0.02% sodium azide and 1 mM EDTA) and 100 ml of fixative (Leukoperm Reagent A, Serotec) is added. After incubation at room temperature for 15 min in the dark, the cells are again washed and 100 ml of permeabilisation reagent (Leukoperm Reagent B, Serotec) is added. FCS (2 ml) is added to each sample for nonspecific blockade of Fc receptors followed by 5 ml of anticytokine antibodies. The cells are incubated for 30 min at room temperature in the dark, washed with PFAE, and resuspended in 1% paraformaldehyde. Samples are kept in the dark at 41C until they are acquired, optimally within 48 hs. (4) Acquisition of data: (a) Equipment. Samples are acquired on an EPICS XL flow cytometer (Beckman Coulter, High Wycombe, UK) equipped with a 488 nm cooled argon laser set-up for four excitation-parameter evaluation and a carousel enabling automated specimen sampling. Other four-colour flow cytometers are appropriate, although the use of different fluorochromes may be necessary.
(b) Acquisition protocol. At the time of acquisition, 50 ml of Flow-Countt fluorospheres (Beckman Coulter) at a fixed concentration is added to each tube. Samples are acquired uncompensated for 300 s or for the time needed to acquire 15 000 cells in the blast region of the linear side scatter (SSC) vs forward scatter (FSC) plot. For data analysis and discrimination of cell subsets, especially of the CPC/small blast populations, it is important that the SSC be set in linear scale during acquisition of the samples or converted from logarithmic to linear scale after acquisition. All the data are saved onto zip disks for transfer to a desktop or laptop computer for analysis. (5) Analysis of data: (a) Software. Flow cytometry acquisition data are analysed with WinList 5.0 (Verity Software House, ME, USA) software.
(b) Compensation. For compensation, a region is made around the lymphocyte area of the SSC vs FSC plot and the CD8 surface marker is evaluated in each channel using the compensation toolbox of the WinList software program. 39 The compensation file is saved for future use should the test sample require re-analysis. Off-line compensation minimises userdependent variability and accommodates revalidation of the analysis and more rigorous examination of the data.
(c) Gating. Regions are set on the myeloid and lymphoid cells based on the CD45 vs SSC plot (accompanying article, Figure  1a (iii) and b(iii) for normal and AML blood, respectively). 40 Lymphoid subsets are further defined based on the CD3 vs CD8 two-parameter histogram (accompanying article, Figure 1a (iv) and b(iv) for normal and AML blood, respectively Figures 1a(ii) and b(ii) for normal and AML, respectively). Based on the number of events in the cell region of interest and the number of events in the bead region and a known bead concentration used at a 1 : 1 ratio during acquisition, the absolute number of cells in the region per microlitre of whole blood is determined. Detailed information for the absolute number calculation, interlaboratory and intralaboratory precision and the accuracy of the cell count Cell number and cytokine secretion in AML N Panoskaltsis et al method using fluorospheres is included in the product monograph provided by Beckman Coulter.
(d) Subtraction. By comparing one-parameter histogram plots for each cell subset, the samples without monensin (control samples) are subtracted from those samples exposed to monensin (test samples) for 6 h (accompanying article, Figure  2 ). The result is representative of the ongoing cytokine production, without added in vitro stimulation, during the 6 h assay. (By using the same anticytokine antibody in the no monensin control rather than an isotype control antibody for the subtraction, potential complications represented by the labelling of preformed cytokine and by a different fluorochrome to antibody ratio that may be present on the isotype control are circumvented.) Super-enhanced D max normalised subtraction (SED) statistics are performed using the WinList software program. If the subtraction results in a negative value (ie, reversal of the test and control histograms to be subtracted), a value of '0' is recorded. Based on the per cent positive after the subtraction and the number of total cells in the regions subtracted, an absolute number of cells expressing cytokine in the region studied is determined per microlitre.
(e) Statistics. SED statistics are used for the channel-bychannel analysis of flow cytometry data using the WinList 5.0 software package. 3 The D max and K-S statistics are used to assess the significance of a positive SED result by calculating the critical D value (D crit ) with the following equation:
where D max is the maximum value between the test and control samples after the two histograms have been converted into cumulative normalised histograms, n 1 is the number of events in the test sample and n 2 is the number of events in the control sample 42 (Table 1 ; North M, Farrant J, Lane A, Knight S, submitted). Note that in the WinList subtraction programme, the D max is given as a per cent value and, when included in the D crit equation, it must be adjusted by dividing by 100. Only positive values that give a D crit with a Po0.05 are accepted (Table 1) . If the D crit (K-S critical value) results in a P40.05, then the percentage of cells producing cytokine in the sample is considered to be '0'.
Time requirement
There is a learning curve associated with the use of WinList. For an operator who has not used this programme before, the time for analysis of a sample may exceed the time for the actual experimental protocol. The excess time required depends on the operator, even for one who is experienced in other flow cytometry analysis programmes.
(1) Total time: 12-14 h (2 days). 
Sensitivity
In this protocol, positive cytokine staining can be blocked using excess anticytokine antibody not conjugated to fluorochrome, thereby indicating the specificity of the technique for the detection of intracellular cytokine expression. If budget allows, cytokine blocking can be carried out with each sample as an internal control for the experiment and as a measure of the sensitivity of the test for cytokine staining.
Specificity/informativeness
The error of the Enhanced Normalised Subtraction (ENS) algorithm (the SED predecessor) has been estimated at 0.85% and compares favourably with other methods for calculating the significance of positive data in flow cytometry analysis. 41 The SED algorithm is an improvement on the ENS method and implies the introduction of less error in the measurement of positive staining. Addition of the K-S statistic to this algorithm enhances the specificity of the technique to a point determined by the operator by use of the D crit equation and application of a P-value that the user finds acceptable (this can range from Po0.001 to 40.200 as indicated in Table 1 ). We have chosen our significance level for this protocol at Po0.05.
Reproducibility/accuracy
(1) Intrasample variability: The total number of cells calculated based on the number of events in the cell region of interest and the number of events in the fluorescent bead region is highly reproducible. When the absolute number of cell subsets from five test samples with no monensin added from one individual is compared, tube-to-tube variability of the total cell number is o10% and usually o5%. To reduce the compound effect of this intrasample variability on subsequent calculations, the mean of all the tubes stained in the no-monensin condition is used as the absolute number of a cell subset in whole blood for each individual. (2) Intersample variability: Intersample variability can be quite marked since a biological system is being characterised. When three healthy individuals had their peripheral blood evaluated up to four times during the course of 1 year using the whole blood assay protocol described here, intracellular cytokine expression was different in each cell subset on each occasion. This intersample difference of cytokine expression is not surprising given the variability displayed by biological systems. However, even though this variability exists, differences in cytokine staining between the healthy cohort and the AML cohort are maintained. (3) WinList subtraction results for intracellular cytokine expression: Initially, we found that the percentage of cells with positive staining and the D value could vary by as much as 10% on repetitive subtractions. However, this variability has been reduced to o1% by adjusting the analysis programme. Ideally, the packet size of data used for analysis should be The cost of the reagents and antibodies used is dependent on the amount used in total. This costing is based on the use of antibodies and protocol-specific reagents at the rate of one vial or bottle per month. Laboratory equipment (such as the flow cytometer) is not included in this cost analysis. The cost can be reduced if more than one patient sample is run at a time.
Troubleshooting
Troubleshooting for the acquisition of samples on the flow cytometer is not included in this guide. For acquisition difficulties, the operator is referred to the manual provided by the manufacturer of the flow cytometer.
Problem Solution
Red cells not lysing K Inadequate mixing after Optilyse added: vortex the sample after the addition of Optilyse for at least 10 s K Aggressive vortex did not improve lysis: add more Optilyse to the sample (500 ml instead of 250 ml), or add more leukoperm (150 ml instead of 100 ml).
Too many red cells left at the time of analysis
K Inadequate red cell lysis: see 'Red cells not lysing' section.
K Inadequate washing of cells between steps: wash the cells 1-3 more times between steps of the experimental protocol.
Cells not viable at time of acquisition K Cells left out too long prior to starting the experiment: process the cells as soon as the sample is procured and at the most within 4 hs.
K Experimental procedure too lengthy: improve the efficiency of the operator. K Cells are shattered because of aggressive mixing of cells with the vortex: samples should be mixed with a vortex enough to lyse the red cells, but not too much such that the leukocytes shatter.
K Paraformaldehyde concentration too high: 1% paraformaldehyde (maximum of 4% for high-risk samples) is adequate for fixing cells.
K Too much ethanol in the samples with monensin: dilute the monensin in medium prior to addition into the samples for a final concentration of 3 mM per FACS tube.
K Too much monensin: in high concentrations, monensin can kill cells. Ensure that 3 mM is used for this 6-hs protocol.
K Cells dying during 6-h incubation: use medium within its date of expiry; ensure the incubator is humidified and at 371C with the appropriate amount of O 2 and CO 2 ; ensure FACS tubes are capped loosely and enough to ensure sterility of the procedure but not so much that the cells suffer from anoxia.
K Time between acquisition of samples and the experimental protocol too long: ideally, samples should be acquired within 48 hs of processing.
Unable to draw regions because of inadequate definition of the cell populations on CD45 vs SSC plot K SSC in logarithmic scale: ensure that the cells are acquired with the SSC in linear scale or that SSC is converted from logarithmic into linear scale after acquisition using the WinList software programme.
K SSC in linear scale but events are still too condensed for adequate definition: during acquisition, the Coulter software allows the operator to stretch the SSC vs FSC plot such that the granulocytes are just at the outer edge of the plot (or if one is not interested in acquiring the granulocytes, the plot can be stretched such that some of them are not included in the plot) allowing better definition of the cells in the lymphoid, blast/CPC, monocyte and dendritic cell regions.
No intracellular cytokines can be measured in the monocytes consistently K Anticytokine antibodies are old: use only antibodies within their date of expiry. K Monensin old or too little: make new stock of monensin and ensure that the final concentration of monensin in the sample tube is 3 mM.
K Subtraction protocol is flawed: ensure that the control sample without monensin is subtracted from the test sample with monensin, the compensation is appropriate and that it is applied to the analysis file, the regions are set appropriately and the gating is logical. Monensin alters the scatter properties of the cells, so ensure that the sample with monensin has the monocyte and CPC/blast region set appropriately on the population being studied prior to the subtraction.
Cell number and cytokine secretion in AML N Panoskaltsis et al (continued)
Problem Solution
No intracellular cytokine production can be measured in the T cells consistently K No intracellular cytokine production is measurable in the monocytes as well: see section 'No intracellular cytokines can be measured in the monocytes consistently'.
K Samples assessed are from healthy persons: this is expected since T cells from healthy individuals often require activation for the measurement of intracellular cytokines -however, the monocytes in these samples should be cytokine-active.
K Samples are from patients with leukaemia: not all leukaemic samples will have T cells that make cytokine without in vitro activation.
K Test the system by providing the T cells with nonspecific stimulation with calcium ionophore (A23187, Sigma, Dorset, UK) 500 ng/ml and phorbol, 12-myristate, 13-Acetate (PMA, Calbiochem) 1 ng/ml in the presence of monensin 3 mM for 6 hs: if the T cells are still not producing cytokine but are expressing CD69 on their surface, re-evaluate the monensin stock, the monensin concentration and the anticytokine antibodies.
High intrasample variability of absolute numbers of cell subsets K Volume of whole blood or of fluorospheres per FACS tube not accurate: the calculation of the absolute number of cells in this assay is dependent on a 1 : 1 ratio of original sample : fluorospheres. Variability in this ratio will vary the absolute cell count.
K Fluorospheres not mixed or mixed too much prior to use: there must be a homogeneous suspension of the fluorospheres prior to use, but mixing should not be so rigorous that bubbles are formed since this alters the volume of fluorospheres added. For low-level cytokine expression, the D crit calculation results in a very large number K D max has not been converted to a decimal number: the D value provided by the WinList programme is recorded as the percentage of the maximum difference between the two normalised curves, after they have been converted into cumulative histograms. The D value must be divided by 100 prior to inclusion in the D crit equation.
